Company's Solutions

Lynx.MD is a secure data network and medical intelligence platform that provides the healthcare ecosystem with quick and secure access to real-world health and patient data for analytics and research. Our cloud-based technology combines AI and NLP capabilities to unlock the potential of structured and unstructured medical data, enabling seamless sharing of medical records, laboratory results, notes, images, genomics, and more, all while ensuring patient data privacy.

Our platform is designed to facilitate data-driven research and innovation, empowering researchers to investigate a wide range of information. With Lynx.MD, organizations can centralize and streamline real-world patient data within a trusted Data Environment (TDE), making it accessible and shareable. This secure environment encourages collaboration between internal and external stakeholders, including developers, data scientists, and researchers, driving the advancement of data-driven healthcare applications and solutions.

Lynx.MD prioritizes the security and privacy of patient data, ensuring that sensitive information remains protected while enabling the exchange of critical medical data. By providing researchers with fast access to high-quality data, our platform fuels innovation and growth, ultimately leading to improved diagnostics, therapeutics, and patient outcomes.

Prominent Case Study

Leveraging Real-World Clinical Data for Advancements in Inflammatory Bowel Disease Treatment

This case study highlights a partnership between Lynx.MD, Prometheus Laboratories Inc., and Gastro Health. The collaboration securely unites over 10-years of de-identified inflammatory bowel disease (IBD) clinical laboratory data and patient information using the Lynx Trusted Data Environment. The objective is to conduct retrospective analysis and research on the effectiveness of Prometheus Anser® IFX therapeutic drug monitoring test in improving patient clinical outcomes and reducing overall healthcare costs in IBD patient management.

Partnership and Objectives: Prometheus Laboratories, a key player in therapeutic drug monitoring, recognizes the immense potential of combining clinical laboratory data with extensive clinical practice data to gain valuable insights into the real-world clinical utility of Anser IFX. By partnering with Lynx.MD and Gastro Health, Prometheus Laboratories gains access to one of the largest IBD real-world data repositories available. The partnership aims to evaluate the precision medicine tool's impact and effectiveness in improving patient outcomes for IBD and other autoimmune diseases.

Data Access and Repository: Gastro Health, one of the largest gastroenterology practices in the United States, contributes to the partnership by providing access to real-world data (RWD). The repository houses a comprehensive collection of data from over 3 million unique patients, curated from more than 400 GI physicians.

Benefits and Collaborative Approach: The collaboration between Lynx.MD, Prometheus Laboratories, and Gastro Health represents a significant step forward in clinical research related to IBD. By securely combining de-identified clinical laboratory data and clinical practice data, researchers gain access to a robust dataset that enables a comprehensive understanding of patient outcomes and care paths. This innovative approach allows researchers to identify new insights, patterns, and trends that can drive advancements in medical knowledge and patient care.

Ensuring Privacy and Compliance: The Lynx.MD platform leverages advanced privacy technology to protect patient data and ensure compliance with GDPR and HIPAA regulations. Researchers can work with real-world patient data, including both unstructured and structured, while maintaining the highest standards of data privacy and security. The platform empowers researchers to merge real-world clinical data from healthcare provider organizations with their own datasets, facilitating a holistic analysis of patient outcomes.

Conclusion: The collaboration between Lynx.MD, Prometheus Laboratories, and Gastro Health demonstrates the power of leveraging real-world clinical data for advancements in IBD treatment. By combining extensive clinical practice data with laboratory data, researchers can gain valuable insights into the effectiveness of therapeutic drug monitoring and its impact on patient outcomes. This collaboration has the potential to improve treatment options, enhance patient care, and contribute to the broader understanding of precision medicine tools in the management of IBD and other autoimmune diseases.